Log in

Relevant bibliographies by topics / Sulodexide / Journal articles

To see the other types of publications on this topic, follow the link: Sulodexide.

Journal articles on the topic 'Sulodexide'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Sulodexide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pompilio, Giuseppe, Davide Integlia, Joseph Raffetto, and Gualtiero Palareti. "Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis." TH Open 04, no. 02 (2020): e80-e93. http://dx.doi.org/10.1055/s-0040-1709731.

Full text

Abstract:

Abstract Objective This network meta-analysis (NMA) assesses the clinical comparative efficacy and safety of sulodexide versus direct-acting oral anticoagulants (DOACs), vitamin K antagonist (VKA), and aspirin in patients with an unprovoked venous thromboembolism (VTE). Methods We conducted a literature search in MEDLINE, Embase, and Cochrane Library using both randomized controlled trials (RCTs) and observational studies. Reduction in recurrent deep venous thrombosis (r-DVT), pulmonary embolism (PE), major bleeding (MB), clinically relevant nonmajor bleeding (CRNMB) were the primary efficacy

APA, Harvard, Vancouver, ISO, and other styles

2

Dobrowolski, Dariusz, and Olga Łach-Wojnarowicz. "Vasoprotective Effect of Sulodexide in Diabetic Retinopathy." Ophthalmology, no. 4 (December 29, 2023): 19–22. http://dx.doi.org/10.5114/oku/177689.

Full text

Abstract:

Diabetes is a group of metabolic diseases, considered a lifestyle disease. Diabetic retinopathy is the leading cause of blindness in working-age adults worldwide. Pathogenetically, due to the changed anionic charge, collagen gradually replaces glycosaminoglycans (GAG) in the basement membrane of retinal capillaries, affecting vascular permeability. Clinically, these changes cause leakage from the retinal capillaries, which leads to the development of microaneurysms and, consequently, the formation of hard effusions (HE). Sulodexide is a glycosaminoglycan containing 80% of small molecular weigh

APA, Harvard, Vancouver, ISO, and other styles

3

Yuan, Tao, Ni Yang, Wei Bi, et al. "Protective Role of Sulodexide on Renal Injury Induced by Limb Ischemia-Reperfusion." Evidence-Based Complementary and Alternative Medicine 2021 (January 30, 2021): 1–9. http://dx.doi.org/10.1155/2021/6629718.

Full text

Abstract:

Background. Though widely known as a potent antithrombin agent with protective effects on the kidney and other remote organs, it is currently ambiguous when it comes to sulodexide’s function on ischemia-reperfusion (I/R) injury. With this research, we pursued to further explore how sulodexide exerts its influence on limb I/R injury, in which deleterious effects on the kidney were what we primarily focused on. Methods. We randomized twenty-four C57BL/6 male rats into three groups, namely, sham operation group (control group), I/R group, and sulodexide pretreatment group. Hematoxylin and eosin s

APA, Harvard, Vancouver, ISO, and other styles

4

Morozov, A. M., A. E. Avanesyan, A. A. Boltik, and A. N. Sergeev. "Possibilities of sulodexide use in clinical practice." Meditsinskiy sovet = Medical Council, no. 6 (May 12, 2023): 289–98. http://dx.doi.org/10.21518/ms2022-050.

Full text

Abstract:

Introduction. Sulodexide is a polymer, the structure of which includes unbranched polysaccharide chains formed by repeating a particular disaccharide unit. This drug was isolated from the endothelium of the pig, and it appeared on the pharmaceutical market in 1974. Sulodexide contains ≈ 80% heparan sulfate (also known as fast-acting heparin) and 20% dermatan sulfate. This drug is produced from the more sulfated waste heparinoids. During production, heparin is chemically decomposed and transformed into the clinical drug Sulodexide. Aim. To estimate the possibilities and prospects of using the d

APA, Harvard, Vancouver, ISO, and other styles

5

Zhao, Qing, Jianyong Yin, Zeyuan Lu, et al. "Sulodexide Protects Contrast-Induced Nephropathy in Sprague-Dawley Rats." Cellular Physiology and Biochemistry 40, no. 3-4 (2016): 621–32. http://dx.doi.org/10.1159/000452575.

Full text

Abstract:

Background: Sulodexide is a powerful antithrombin agent with reno-protective property. However, whether it has beneficial effects on Contrast-Induced Nephropathy (CIN) remained elusive. In the current study, we evaluated the therapeutic effects of Sulodexide on CIN and investigated the potential mechanisms. Methods: CIN model was induced by intravenous injection of indomethacin, followed by Ioversol and L-NAME. Sprague-Dawley rats were divided into 4 groups: control group, CIN group, CIN+vehicle group (CIN rats pretreated with vehicle) and CIN+ Sulodexide (CIN rats pretreated with Sulodexide).

APA, Harvard, Vancouver, ISO, and other styles

6

Gonzalez-Ochoa, Alejandro. "Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled Trial." Blood 138, Supplement 1 (2021): 667. http://dx.doi.org/10.1182/blood-2021-151814.

Full text

Abstract:

Abstract Background: SARS-CoV-2 can induce several vascular endothelial-dependent systemic complications and treatment targeting endothelial cells has been suggested. Sulodexide is a heparin and glycosaminoglycan compound that has pleiotropic properties within the vascular endothelium that can prove beneficial in COVID-19 patients. Aims: We aimed to evaluate the effect of sulodexide when used in the early clinical stages of COVID-19. Methods: In an outpatient setting, we conducted a randomized placebo-controlled trial. Key inclusion criteria were patients within three days of COVID-19 clinical

APA, Harvard, Vancouver, ISO, and other styles

7

Scondotto, Gaetano, Giancarlo Agnelli, Daniele Aloisi, Ernesto Palazzini, Villiam Zamboni, and Sergio Coccheri. "Randomised, Double Blind, Multicentre, Placebo Controlled Study of Sulodexide in the Treatment of Venous Leg Ulcers." Thrombosis and Haemostasis 87, no. 06 (2002): 947–52. http://dx.doi.org/10.1055/s-0037-1613116.

Full text

Abstract:

SummarySulodexide, a highly purified glycosaminoglycan, was investigated for treatment of venous leg ulcers. Patients (n = 235) undergoing local treatment including wound care and compression bandaging, were randomised to receive either sulodexide or matching placebo for three months. Primary study endpoint was complete ulcer healing after 2 months; secondary endpoints were ulcer healing at 3 months and the time-course changes of ulcer areas.The proportion of patients with complete ulcer healing was higher with sulodexide at 2 months (p = 0.018) and 3 months. The “number needed to treat” to ob

APA, Harvard, Vancouver, ISO, and other styles

8

Reyes, Eugenio B., Paula Victoria Catherine Y. Cheng-Bromeo, and Nigel Jeronimo C. Santos. "The Effect of Sulodexide on the Incidence of Cardiovascular Outcomes in Patients With Vascular Disorders." Philippine Journal of Cardiology 53, no. 1 (2025): 87–97. https://doi.org/10.69944/pjc.06659058d5.

Full text

Abstract:

Background and Objectives: Among patients with macrovascular and microvascular disease, we investigated the association between sulodexide and cardiovascular (CV) outcomes and adverse events. Methods: We conducted a meta-analysis of randomized control trials (RCTs) reporting CV outcomes and adverse events in patients with vascular disease receiving sulodexide for any indication versus control. The following outcomes were investigated: any CV event, myocardial infarction, CV death, bleeding events and gastrointestinal symptoms. Results: Twelve studies with a total of 8,436 patients were include

APA, Harvard, Vancouver, ISO, and other styles

9

Satirapoj, Bancha, Wisit Kaewput, Ouppatham Supasyndh, and Prajej Ruangkanchanasetr. "Effect of Sulodexide on Urinary Biomarkers of Kidney Injury in Normoalbuminuric Type 2 Diabetes: A Randomized Controlled Trial." Journal of Diabetes Research 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/172038.

Full text

Abstract:

Glycosaminoglycans or sulodexide has shown benefits in early experimental diabetic nephropathy (DN) models, but its efficacy in patients with early stage of DN is unknown.Methods. Twenty patients were randomly assigned to the placebo group and another 20 patients were randomly assigned to receive sulodexide 100 mg/day for 14 weeks. Primary outcome was a change of urinary TGF-beta1, albuminuria, and glomerular filtration rate (GFR). All patients had stable metabolic profiles for at least 90 days before randomization.Results. Urinary TGF-beta1 increased significantly in the placebo group but did

APA, Harvard, Vancouver, ISO, and other styles

10

Gonzalez-Ochoa, Alejandro J., Joseph D. Raffetto, Ana G. Hernández, et al. "Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial." Thrombosis and Haemostasis 121, no. 07 (2021): 944–54. http://dx.doi.org/10.1055/a-1414-5216.

Full text

Abstract:

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce several vascular endothelial-dependent systemic complications, and sulodexide has pleiotropic actions on the vascular endothelium, which may prove beneficial. We aimed to assess the effect of sulodexide when used within 3 days of coronavirus disease 2019 (COVID-19) clinical onset. We conducted a randomized placebo-controlled outpatient trial. To be included, patients must have been at high risk for severe clinical progression. Participants received sulodexide (oral 1,000 LRU/d) or placebo for 21 days. The primary e

APA, Harvard, Vancouver, ISO, and other styles

11

Morozov, А., А. Sergeev, А. Boltik, А. Aslakhanova, and К. Ispieva. "Sulodexide in clinical practice: possibilities and prospects of its use." Vrach 35, no. 1 (2024): 55–58. http://dx.doi.org/10.29296/25877305-2024-01-11.

Full text

Abstract:

Objective: to analyze up-to-date information about the efficiency of using sulodexide n clinical practice. Current publication on the efficacy and safety of sulodexide, as well as information on the pathogenesis and clinical manifestations of chronic venous insufficiency, microvascular angina, venous thromboembolic events, and diabetes mellitus have been sought for and analyzed Most clinical trials show that sulodexide exerts anti-inflammatory, endothelium-protective, and pleotrophic effects, by confirming its potential efficacy in the treatment of cardiovascular diseases, in particular chroni

APA, Harvard, Vancouver, ISO, and other styles

12

El Beaino, Marc, Meghan K. McCaskey, and Elie Eter. "Sulodexide Monotherapy in Chronic Idiopathic Subjective Tinnitus: A Randomized Controlled Trial." Otolaryngology–Head and Neck Surgery 158, no. 6 (2018): 1107–12. http://dx.doi.org/10.1177/0194599818767618.

Full text

Abstract:

Objective To report the therapeutic value of sulodexide monotherapy in the management of patients with chronic subjective idiopathic tinnitus. Study Design Randomized double-blinded controlled trial. Setting Single tertiary care institution. Subjects and Methods Observations from 124 patients who received either sulodexide or placebo were collected from the patients’ medical records. Computer-generated tables were used to allocate treatments. Patients took 1 tablet of the drug or placebo each morning and evening for 40 consecutive days. The response was assessed by the Tinnitus Handicap Invent

APA, Harvard, Vancouver, ISO, and other styles

13

Petrikov, A. S., D. V. Dudin, S. V. Zaitsev, V. R. Eirikh, V. I. Belykh, and Ya N. Shoikhet. "The influence of prolonged antithrombotic therapy on the development of post-thrombotic syndrome in patients with proximal deep vein thrombosis of the lower limbs." Ambulatory surgery: hospital-replacing technologies, no. 3-4 (December 4, 2018): 83–88. http://dx.doi.org/10.21518/1995-1477-2018-3-4-83-88.

Full text

Abstract:

The article is devoted to the incidence and severity of post-thrombotic syndrome (PTS), the odds ratio (OR) of PTS development in patients with previous proximal deep vein thrombosis (DVT) against the background of prolonged antithrombotic warfarin and sulodexide (SD) therapy (ATT) with due account for safety and development of clinically significant bleeding (CSB) during the year. A total of 130 patients aged 18 to 69 years with acute proximal DVT were enrolled in the comparative prospective study. Group I included 64 patients (31 men and 33 women), who received vitamin K antagonists (warfari

APA, Harvard, Vancouver, ISO, and other styles

14

Zhaivoronok, N. S., V. V. Egorov, G. P. Smoliakova, et al. "Clinical experience of combined use of the angiogenesis inhibitor aflibercept in the treatment of retinal vein occlusions." Modern technologies in ophtalmology, no. 2 (April 13, 2022): 195–202. http://dx.doi.org/10.25276/2312-4911-2022-2-195-202.

Full text

Abstract:

Purpose. To evaluate the effectiveness of the combined use of aflibercept and sulodexide in the treatment of macular edema (ME) in retinal vein occlusions (RVO). Material and methods. In the course of the study, 30 patients with MO with acute respiratory infections not exceeding 1.5 months ago were monitored. All underwent a standard ophthalmological examination, as well as optical coherence tomography with angiography function and electrophysiological studies. To assess the effectiveness of the combined use of aflibercept and sulodexide, all patients were divided into two groups. In patients

APA, Harvard, Vancouver, ISO, and other styles

15

Siddiqui, Fakiha, Debra Hoppensteadt, Emily Bontekoe, Ambar Farooqui, Walter Jeske, and Jawed Fareed. "Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components." Clinical and Applied Thrombosis/Hemostasis 26 (January 1, 2020): 107602962095491. http://dx.doi.org/10.1177/1076029620954913.

Full text

Abstract:

Introduction: Sulodexide represents a mixture of fast-moving heparin (FMH) and dermatan sulfate (DS) and has been used for the management of venous diseases such as DVT and related disorders. The purpose of this study is to compare sulodexide and its components with unfractionated heparin (UFH) to determine its suitability for the indications in which UFH is used. Materials and Method: Active pharmaceutical ingredients (API) versions of sulodexide, FMH and DS were obtained from Alfasigma. API versions of UFH were obtained from Medefil Inc. Normal human citrated plasma was obtained from blood b

APA, Harvard, Vancouver, ISO, and other styles

16

Dauth, Alice, Andrzej Bręborowicz, Yue Ruan, et al. "Sulodexide Prevents Hyperglycemia-Induced Endothelial Dysfunction and Oxidative Stress in Porcine Retinal Arterioles." Antioxidants 12, no. 2 (2023): 388. http://dx.doi.org/10.3390/antiox12020388.

Full text

Abstract:

Diabetes mellitus may cause severe damage to retinal blood vessels. The central aim of this study was to test the hypothesis that sulodexide, a mixture of glycosaminoglycans, has a protective effect against hyperglycemia-induced endothelial dysfunction in the retina. Functional studies were performed in isolated porcine retinal arterioles. Vessels were cannulated and incubated with highly concentrated glucose solution (HG, 25 mM D-glucose) +/− sulodexide (50/5/0.5 μg/mL) or normally concentrated glucose solution (NG, 5.5 mM D-glucose) +/− sulodexide for two hours. Endothelium-dependent and end

APA, Harvard, Vancouver, ISO, and other styles

17

Gazizova, G. Kh, A. G. Yashchuk, A. V. Maslennikov, L. A. Dautova, and G. Yu Battalova. "Evaluation of the efficacy of different treatment modalities for chronic atrophic endometritis." Voprosy ginekologii, akušerstva i perinatologii 21, no. 4 (2022): 152–58. http://dx.doi.org/10.20953/1726-1678-2022-4-152-158.

Full text

Abstract:

Objective. To study the efficacy of different treatment regimens in patients with chronic atrophic endometritis against the background of endometrial hemodynamic dysfunction using intrauterine perfusion of platelet-rich plasma (PRP therapy) or sulodexide, or a combination of PRP therapy and sulodexide. Patients and methods. This study included 116 patients with morphologically confirmed diagnosis of chronic endometritis. Patients were divided into three groups: group 1 (n = 18) received PRP therapy in addition to basic therapy; group 2 (n = 68) received basic therapy and sulodexide; group 3 (n

APA, Harvard, Vancouver, ISO, and other styles

18

Gromova, O. A., I. Yu Torshin, and A. G. Chuchalin. "On the influence of glycocalyx on NO biosynthesis: The role of sulodexide." Meditsinskiy sovet = Medical Council, no. 5 (May 4, 2025): 196–205. https://doi.org/10.21518/ms2025-008.

Full text

Abstract:

The glycocalyx is a special ultra-fine structure of glycosaminoand proteoglycans, 0.2–5 μm thick, covering the endothelium. Maintenance of the mechanisms of synthesis and secretion of the signaling molecule NO, this regulator of vascular tone, mitochondrial respiration, neurotransmission and immunity, occurs through the reconstruction of the glycocalyx. Sulodexide is a combination of natural glycosaminoglycans – heparan sulfate and dermatan sulfate, which are part of the glycocalyx. The antithrombotic effect of sulodexide, realized through the suppression of platelet adhesion and aggregation,

APA, Harvard, Vancouver, ISO, and other styles

19

Emanova, L. P., G. P. Smoliakova, V. V. Egorov, et al. "Methods for improving the efficiency of medical rehabilitation of patients with acute ischemic neuroopticopathy." Modern technologies in ophtalmology, no. 2 (April 13, 2022): 187–94. http://dx.doi.org/10.25276/2312-4911-2022-2-187-194.

Full text

Abstract:

Purpose. To study the effectiveness of complex pathogenetically directed treatment of patients with anterior ischemic neuroopticopathy (AIN), including the use of Sulodexide and intermittent retrobulbar infusion of neuroprotective drugs in combination with cranio-orbital magnetic stimulation. Material and methods. 21 patients with the acute phase of AIN aged 37 to 67 years (mean 52.3 ± 4.5 years). Depending on the features of the additions to the ongoing complex therapy, the patients were divided into two groups: the main group (10 people), the treatment regimen of which additionally included

APA, Harvard, Vancouver, ISO, and other styles

20

Gaddi, A., C. Galetti, B. Illuminati, and S. Nascetti. "Meta-Analysis of Some Results of Clinical Trials on Sulodexide Therapy in Peripheral Occlusive Arterial Disease." Journal of International Medical Research 24, no. 5 (1996): 389–406. http://dx.doi.org/10.1177/030006059602400501.

Full text

Abstract:

The aim was to look at the effect of sulodexide in diabetic and non-diabetic patients with peripheral occlusive arterial disease (POAD), by verifying, through meta-analysis of Italian data, if the drug affects the clinical course of claudication or the main risk factors for POAD. Sulodexide increases the pain-free walking distance (benefit 36% vs controls, P < 0.001). The meta-analysis confirmed the effectiveness of sulodexide in improving claudication (lower limit of the 95% CI for overall odds ratio always >1). There was a marked effect in lowering triglycerides (overall −28%, P = 0.00

APA, Harvard, Vancouver, ISO, and other styles

21

Semenova, Iya Vladimirovna, Lyudmila Alexandrovna Chugunova, Alexander Viktorovich Il'in, et al. "Effect of glycosoaminoglycans on the clinical course of diabetic nephropathy at the stage of microalbuminuria in patients with type 2 diabetes mellitus." Diabetes mellitus 13, no. 2 (2010): 34–39. http://dx.doi.org/10.14341/2072-0351-5671.

Full text

Abstract:

Aim. To evaluate clinical efficiency of sulodexide (glycosoaminoglycan) for the treatment of patients with type 2 diabetes mellitus (DM2) and diabeticnephropathy (DN) at the stage of microalbuminuria (MAU). Materials and methods. A total of 30 patients with DM2 and MAU were examined 15 of whom were given sulodexide (200 mg daily) for 6 months.The following parameters were measured before, 3 and 6 months after the onset of therapy: HbA1c level, biochemical characteristics, highly sensitiveCRB, MAU in morning urine samples, soluble intercellular and vascular cell adhesion molecules-1, blood coag

APA, Harvard, Vancouver, ISO, and other styles

22

Seguban, Joseph Marc, Michelle Andrea Uy-Reyes, Allan Lim, et al. "Sulodexide as an Adjunct for the Management of Venous Ulcers: A Meta-analysis." Philippine Journal of Cardiology 45, no. 1 (2017): 24–30. http://dx.doi.org/10.69944/pjc.71188b6946.

Full text

Abstract:

Background: Venous leg ulcer is a common, chronic recurring condition that causes pain and disability. If not treated, it can lead to severe infection and malignant transformation. Sulodexide is a highly purified glycosaminoglycan with anti-thrombotic, anti-fibrinolytic and anti-inflammatory properties that make it a suitable agent for the management of venous leg ulcers. At present, there is insufficient evidence to support the efficacy of the use of sulodexide in the management of venous leg ulcers and ulcer pain. Objective: This meta-analysis aims to determine the efficacy of sulodexide in

APA, Harvard, Vancouver, ISO, and other styles

23

Chen, Wenjun, and Xiaoming Zhou. "Treatment of peripheral neuropathy in type 2 diabetes with epalrestat combined with sulodexide." Tropical Journal of Pharmaceutical Research 23, no. 12 (2025): 2017–23. https://doi.org/10.4314/tjpr.v23i12.6.

Full text

Abstract:

Purpose: To analyze the efficacy of epalrestat combined with Sulodexide in the treatment of diabetic peripheral neuropathy in type 2 diabetes. Methods: A total of 140 patients with type 2 diabetic peripheral neuropathy, who were treated at the Zhanjiang Central People's Hospital between February 2022 and February 2023, were selected as subjects. They were randomly divided into two groups using a computer- generated random number table. The control group (n = 70) received epalrestat treatment, while the study group (n = 70) was treated with a combination of epalrestat and Sulodexide11. Efficacy

APA, Harvard, Vancouver, ISO, and other styles

24

Yongwatana, Kachonsak, Ouppatham Supasyndh, and Bancha Satirapoj. "Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria." Journal of Diabetes Research 2020 (August 11, 2020): 1–6. http://dx.doi.org/10.1155/2020/2984680.

Full text

Abstract:

Background. Glycosaminoglycan plays an important role in the maintenance of glomerular charge selectivity of diabetic nephropathy. Sulodexide, a mixture of naturally occurring glycosaminoglycan polysaccharide components, has shown a nephroprotective effect in an experimental model of diabetic nephropathy. Although sulodexide reduced albuminuria in patients with type 1 and type 2 diabetes, long-term effects in patients with type 2 diabetes with significant proteinuria have not been established. Objectives. The study was aimed at investigating the effects of sulodexide on proteinuria and renal f

APA, Harvard, Vancouver, ISO, and other styles

25

Vorontsov, A. V., I. I. Dedov, M. V. Shestakova, T. M. Milenkaya, and A. P. Knyazeva. "Glycosaminoglycans in therapy of diabetic nephropathy." Problems of Endocrinology 42, no. 5 (1996): 14–18. http://dx.doi.org/10.14341/probl12082.

Full text

Abstract:

Sulodexide, a drug containing glycosaminoglycans, was used in the treatment of patients with type I diabetes. Along with their effects on the blood clotting system, glycosaminoglycans are capable of preventing the mesangial proliferation and hyperproduction of extracellular matrix, as well as thickening of the glomerular basal membrane and impairment of its permeability and charge selection. A reliable antiproteinuric effect of the drug was noted, persisting for 6 weeks after it was discontinued; the excretion of protein with the urine reliably decreased in patients with both, microalbuminuria

APA, Harvard, Vancouver, ISO, and other styles

26

Borawski, Jacek, Miroslaw Dubowski, Krystyna Pawlak та Michal Mysliwiec. "Effect of Sulodexide on Plasma Transforming Growth Factor-β1 in Healthy Volunteers". Clinical and Applied Thrombosis/Hemostasis 16, № 1 (2008): 60–65. http://dx.doi.org/10.1177/1076029608326170.

Full text

Abstract:

It is unknown whether the glycosaminoglycan drug sulodexide interferes with transforming growth factorβ1—a member of heparin-binding family and a potent regulator of human biology and diseases. Hence, a 2-week pilot study was performed in 11 healthy men. Sulodexide was initially administered intravenously in a single dose, then—orally for 12 days and—again intravenously on study completion. Initial injection had no effect on activated form of the growth factor measured in plasma after 10 and 120 min; no change was also observed after 120 min from drug ingestion on day 7. On final intravenous a

APA, Harvard, Vancouver, ISO, and other styles

27

Gavrilova, Natalya Alexandrovna, and Olga Evgen'evna Tishchenko. "Vliyanie sulodeksida na funktsional'noe sostoyanie endoteliya u bol'nykh s sakharnym diabetom i diabeticheskoyretinopatiey." Diabetes mellitus 14, no. 2 (2011): 66–68. http://dx.doi.org/10.14341/2072-0351-5637.

Full text

Abstract:

Aim. To study effect of sulodexide (Vessel Due F) on the functional state of endothelium in patients with diabetic retinopathy. Materials and methods. A total of 37 patients with DR were divided in 2 groups and treated with sulodexide. Group 1 comprised 16 patients withnon-proliferative DR, group 2 included 21 patients with preproliferative DR. The functional state of endothelium was estimated from the plasma andserum levels of endothelial factors (sVCAM, endothelin, nitric oxide, t-PA, Willebrand factor). Results. The measurement of the initial levels of endothelial factors in both groups rev

APA, Harvard, Vancouver, ISO, and other styles

28

Farooqui, Ambar, Debra Hoppensteadt, Omer Iqbal, et al. "Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies." Blood 134, Supplement_1 (2019): 2446. http://dx.doi.org/10.1182/blood-2019-131825.

Full text

Abstract:

Introduction: Sulodexide represents a glycosaminoglycan derived antithrombotic agent which is clinically used for the management of vascular disorders and is pharmacologically active after both parenteral and oral administration. Similar to unfractionated heparin (UFH), this drug is derived from porcine mucosal tissue and is composed of a mixture of fast moving low molecular weight heparin (molecular weight 7.0 Kda) and dermatan sulfate (molecular weight 20 Kda). The USP anticoagulant potency of sulodexide is 92 + 4 USP units / mg in contrast to unfractionated heparin which is 200 U/mg. The pu

APA, Harvard, Vancouver, ISO, and other styles

29

Corsi, C., L. Bocci, C. Cipriani, A. Gazzini, and E. Marrapodi. "The Effectiveness of Glycosaminoglycans in Peripheral Vascular Disease Therapy: A Clinical and Experimental Trial." Journal of International Medical Research 13, no. 1 (1985): 40–47. http://dx.doi.org/10.1177/030006058501300106.

Full text

Abstract:

Thirty patients suffering from peripheral vascular disease (stage–II according to Fontaine) were included in a double-blind study aimed at assessing the efficacy of a high-dose glycosaminoglycan (GAG) (Sulodexide) both in terms of laboratory parameters, such as lipid metabolism and blood coagulation components, and instrumental procedures (strain-gauge plethysmography). Compared with the fifteen control patients (treated with placebo), the fifteen patients treated with Sulodexide showed a signficant decrease in blood triglycerides and fibrinogen as well as a significantly increased HDL-cholest

APA, Harvard, Vancouver, ISO, and other styles

30

Zaniolo, Orietta, and Mario Eandi. "Sulodexide: implicazioni cliniche ed economiche." Farmeconomia. Health economics and therapeutic pathways 6, no. 2 (2005): 105–18. http://dx.doi.org/10.7175/fe.v6i2.826.

Full text

Abstract:

Sulodexide is a highly purified glycosaminoglycan approved for leg ulcers treatment. It contains two principal components: heparan sulfate, a fast-moving heparin fraction, (80%) and dermatan sulfate (20%). Sulodexide is available as an oral agent and as an injectable preparation. Its pharmacological action is obtained by dose-dependent coagulation factors inhibition: dermatan sulfate upgrades the physiological action of a selective thrombin inhibitor, heparin cofactor II, and heparan sulfate depresses activated factor X, via an increase of antithrombin III action. The antithrombotic action is

APA, Harvard, Vancouver, ISO, and other styles

31

Emanova, L. P., G. P. Smoliakova, V. V. Egorov, et al. "Effectiveness complex treatment of isolated optic disk vasculitis." Modern technologies in ophtalmology, no. 1 (May 29, 2021): 158–62. http://dx.doi.org/10.25276/2312-4911-2021-1-158-162.

Full text

Abstract:

Purpose. To study effectiveness combination of topical corticosteroid therapy and sulodexide in complex treatment of patients with isolated optic disk vasculitis (IODV). Material and methods. The study included 17 patients with IODV (middle age was 26.7±6.2 years on average). Depending on different of additions to topical corticosteroid therapy, the patients were divided into two groups: the main group (8 people), treatment regimen of which additionally included sulodexide during and after the end of inpatient treatment, and the control group (9 people), which at inpatient treatment sulodexide

APA, Harvard, Vancouver, ISO, and other styles

32

Bikdeli, Behnood, Saurav Chatterjee, Ajay J. Kirtane, et al. "Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials." Seminars in Thrombosis and Hemostasis 46, no. 08 (2020): 908–18. http://dx.doi.org/10.1055/s-0040-1716874.

Full text

Abstract:

AbstractThrombotic cardiovascular disease (myocardial infarction [MI], stroke, and venous thromboembolism [VTE]) remains a major cause of death and disability. Sulodexide is an oral glycosaminoglycan containing heparan sulfate and dermatan sulfate. We conducted a systematic review and meta-analysis to determine the cardiovascular efficacy, and safety of sulodexide versus control in randomized controlled trials (RCTs). We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for RCTs reporting cardiovascular outcomes in patients receiving sulodexide versus control (pl

APA, Harvard, Vancouver, ISO, and other styles

33

Mozgovaya, E. V., T. B. Postnikova, and I. Yu Kogan. "Experience with pathogenetic effects of a complex medication containing glycosaminoglycans on glycocalyx in a patient with recurrent severe pre-eclampsia." Voprosy ginekologii, akušerstva i perinatologii 24, no. 1 (2025): 132–36. https://doi.org/10.20953/1726-1678-2025-1-132-136.

Full text

Abstract:

This article examines the endothelial protective role of the vascular glycocalyx. Macromolecules protruding above the surface of endothelial cells, consisting of proteoglycans, glycoproteins and especially glycosaminoglycans, due to their negative charge prevent the contact of protein molecules, platelets, white blood cells and adhesion molecules with the endothelium. It is the destruction of the glycocalyx that leads to the development of vascular complications and underlies many diseases. The pathogenesis of pre-eclampsia is also directly related to thinning and destruction of the glycocalyx

APA, Harvard, Vancouver, ISO, and other styles

34

Topchiy, I. I., P. S. Semenovykh, V. Yu Galchinskaya, and Yu S. Yakimenko. "PECULIARITIES OF NEPHROPROTECTIVE EFFECT OF SULODEXIDE IN PATIENTS WITH DIABETIC NEPHROPATHY." Ukrainian Journal of Nephrology and Dialysis, no. 4(40) (December 12, 2017): 19–24. http://dx.doi.org/10.31450/ukrjnd.4(40).2013.02.

Full text

Abstract:

Introduction. Monocyte chemoattractant protein type 1 (MCP-1) and plasminogen activator inhibitor type 1 (PAI-1) play a key role in inflammation, fibrosis and progression of renal dysfunction. Sulodexide advantages in vascular pathology treatment were proved by clinical trials, however, its efficiency in diabetic nephropathy (DN) was investigated insufficiently. The aim of the present work – to study the influence of sulodexide on clinical and laboratory parametres, MCP-1 and PAI-1 levels in blood plasma of patients with DN. Materials and methods. 76 type 2 diabetic patients with d

APA, Harvard, Vancouver, ISO, and other styles

35

Sosińska, Patrycja, Ewa Baum, Beata Maćkowiak, et al. "Sulodexide Reduces the Proinflammatory Effect of Serum from Patients with Peripheral Artery Disease in Human Arterial Endothelial Cells." Cellular Physiology and Biochemistry 40, no. 5 (2016): 1005–12. http://dx.doi.org/10.1159/000453157.

Full text

Abstract:

Background/Aims: Dysfunction of the arterial endothelial cells promotes the progression of atherosclerosis. We studied how exposure of human arterial endothelial cells to atherosclerotic serum from patients with peripheral artery disease changes the secretory activity of these cells, and whether that reaction is modified by sulodexide. Methods: Endothelial cells in in vitro culture were exposed to standard culture medium ± 100pg/mL Interleukin-1(IL-1) or to medium supplemented with 20% atherosclerotic serum. Afterwards, the expression of genes responsible for the synthesis of Interleukin-6 (IL

APA, Harvard, Vancouver, ISO, and other styles

36

Skvortsov, Vsevolod Vladimirovich, Ekaterina Mikhailovna Skvortsova, and Kristina Aleksandrovna Durnoglazova. "Diagnosis and treatment of thromboembolic complications: modern recommendations." Spravočnik vrača obŝej praktiki (Journal of Family Medicine), no. 6 (June 5, 2022): 43–49. http://dx.doi.org/10.33920/med-10-2206-06.

Full text

Abstract:

The article considers the risk of venous thromboembolism and evaluates the evidence for the effectiveness of primary preventive measures, in particular with the drug Sulodexide. Oral administration of Sulodexide is used in prevention and treatment of venous thromboembolism in patients with hemorrhagic risk. The article provides recommendations on the most clinically and cost-effective measures to reduce the risk of venous thromboembolism, taking into account the potential risks of various options for the prevention of venous thromboembolism (VTE) in patients at high risk of bleeding, who would

APA, Harvard, Vancouver, ISO, and other styles

37

Masotti, Luca. "Sulodexide. Pharmacokinetics, pharmacodynamics, and mechanism of action." Clinical Management Issues 4, no. 4S (2015): 17–21. http://dx.doi.org/10.7175/cmi.v4i4s.1088.

Full text

Abstract:

Sulodexide is a highly purified preparation containing glycosaminoglycans composed from heparin-like and dermatan fractions. It is similar to unfractionated heparin, but it shows a prolonged half-life, a higher bioavability and a reduced effect on bleeding parameters. This article describes the mechanism of action of sulodexide and its pharmacokinetic and pharmacodynamic parameters, listing the most important pharmacologic studies published.

APA, Harvard, Vancouver, ISO, and other styles

38

Okopień, Bogusław, Mateusz Maligłówka, and Magdalena Anton. "Sulodexide – indications for use." Medycyna Faktów 12, no. 3 (2019): 246–49. http://dx.doi.org/10.24292/01.mf.0319.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Carroll, B. J., G. Piazza, and S. Z. Goldhaber. "Sulodexide in venous disease." Journal of Thrombosis and Haemostasis 17, no. 1 (2018): 31–38. http://dx.doi.org/10.1111/jth.14324.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ofosu, Frederick. "Pharmacological Actions of Sulodexide." Seminars in Thrombosis and Hemostasis 24, no. 02 (1998): 127–38. http://dx.doi.org/10.1055/s-2007-995831.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Nadroparin calcium/ozagrel/sulodexide." Reactions Weekly &NA;, no. 1418 (2012): 33. http://dx.doi.org/10.2165/00128415-201214180-00122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Mielikova, Tatiana Anatolevna, and Dmitrii Nikolaevich Shapoval. "CURRENT APPROACHES TO TREAT GESTATIONAL PERIOD COMPLICATIONS IN WOMEN WITH GRAVES’ DISEASE." International Medical Journal, no. 4 (February 26, 2020): 31–34. http://dx.doi.org/10.37436/2308-5274-2019-4-7.

Full text

Abstract:

The most common cause of hyperthyroidism in pregnant women is recognized by Graves' disease. Because it leads to serious complications in the mother and fetus, timely correction of disorders of homeostasis provides a successful outcome of pregnancy. In order to study the effectiveness of the drug with the active substance sulodexide in pregnant women with Graves' disease, 28 women were examined for the possibility of reducing obstetric and perinatal complications. They performed general clinical examinations, performed an extensive hemostasis, determined the fetal fetal condition. It has been

APA, Harvard, Vancouver, ISO, and other styles

43

Cha, Chang Min, Jae Wan Lim, Chang Zoo Kim, Seung Uk Lee, and Sang Joon Lee. "Long-term Longitudinal Analysis of Subfoveal Choroidal Thickness Following Sulodexide Treatment in Diabetic Retinopathy Patients." Journal of the Korean Ophthalmological Society 64, no. 12 (2023): 1208–17. http://dx.doi.org/10.3341/jkos.2023.64.12.1208.

Full text

Abstract:

Purpose: To evaluate the two-year longitudinal changes in subfoveal choroidal thickness (CT) following sulodexide treatment in patients with diabetic retinopathy.Methods: Thirty-eight eyes from patients with diabetic retinopathy, followed for a minimum of two years after sulodexide administration, were included. Subfoveal CT, measured using optical coherence tomography, was analyzed prospectively. Variables including age, sex, duration of diabetes mellitus, HbA1c, blood pressure, sulodexide treatment duration, refractive error, axial length, central macular thickness (CMT), visual acuity, lase

APA, Harvard, Vancouver, ISO, and other styles

44

Katelnitsky, I. I., V. V. Darvin, and A. A. Zorkin. "Comprehensive treatment of patients with chronic limb-threatening ischaemia: are we using all the possibilities of anticoagulant therapy?" Russian Medical Inquiry 4, no. 7 (2020): 445–51. http://dx.doi.org/10.32364/2587-6821-2020-4-7-445-451.

Full text

Abstract:

Background: medical correction of the hemostatic system is one of the most important directions for complex treatment of obliterating diseases of lower limbs arteries (ODLLA), including cases of chronic limb-threatening ischaemia (CLTI).Aim: to evaluate the efficacy and safety of the sulodexide use in patients with ODLLA when conducting a comprehensive treatment of CLTI.Patients and Methods: 520 patients underwent two-center prospective study, 318 of whom (211 — with signs of ODLLA, 107 — without signs of CLTI) underwent revascularization interventions, whereas, 202 patients with CLTI received

APA, Harvard, Vancouver, ISO, and other styles

45

Martynov, Artur, Olena Grishyna, and Olena Menkus. "(Information letter) A treatment method for Covid-19 infection in patients with inflammatory joint diseases." Annals of Mechnikov Institute, no. 4 (December 4, 2023): 156–57. https://doi.org/10.5281/zenodo.10257524.

Full text

Abstract:

The implementation involved a new method of treating COVID-19 infection in patients with inflammatory joint diseases. The method includes the addition of sulodexide to standard therapy in outpatient settings. An open randomized controlled trial was conducted with 53 patients suffering from inflammatory joint diseases. The patients were divided into two groups; group 1 received sulodexide in addition to standard therapy for COVID-19 while group 2 received only standard therapy. The results showed that supplementing the standard therapy of COVID-19 with sulodexide in patients with inflammatory j

APA, Harvard, Vancouver, ISO, and other styles

46

Maslennikov, А. V., А. G. Yashchuk, G. Kh Gazizova, and E. F. Berdigulova. "Effectiveness of using heparinoids in patients with endometrial dysfunction and concomitant undifferentiated connective tissue disease." Voprosy ginekologii, akušerstva i perinatologii 19, no. 4 (2020): 50–56. http://dx.doi.org/10.20953/1726-1678-2020-4-50-56.

Full text

Abstract:

Objective. To study the effectiveness of heparinoid sulodexide in complex therapy of patients with endometrial dysfunction and concomitant undifferentiated connective tissue disease (UCTD). Patients and methods. We examined 88 patients with UCTD and endometrial dysfunction (the «thin endometrium» phenomenon). The therapeutic regimen of 41 patients (group 1а) additionally to cyclical therapy with 17-b estradiol and didrogesterone was supplemented by continuous heparinoid sulodexide for 3 menstrual cycles (MC), 20 patients (group 1b) in addition to cyclical therapy received the heparinoid from t

APA, Harvard, Vancouver, ISO, and other styles

47

Zilişteanu, Diana-Silvia, Teodora Atasie, and M. Voiculescu. "Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies." Romanian Journal Of Internal Medicine 53, no. 2 (2015): 161–69. http://dx.doi.org/10.1515/rjim-2015-0022.

Full text

Abstract:

Abstract Background and Aims. Sulodexide has been reported to have antiproteinuric and nephroprotective properties. We investigated the effects of long-term low-dose Sulodexide on proteinuria and renal function in patients with chronic kidney disease (CKD) caused by diabetic nephropathy (DN), hypertensive nephropathy (HN) and primary glomerulonephritis (GN). Material and Methods. 100 patients with CKD received low-dose Sulodexide 50 mg/day for 12 months. Treatment efficacy was evaluated as proteinuria reduction compared to baseline; response was defined as a decline in proteinuria below 0.3 g/

APA, Harvard, Vancouver, ISO, and other styles

48

Shtoda, Yu M., N. A. Slesarenko, A. L. Bakulev, S. R. Utz, and A. N. Platonova. "Endothelial dysfunction and its treatment in psoriasis patients." Vestnik dermatologii i venerologii 91, no. 1 (2015): 62–66. http://dx.doi.org/10.25208/0042-4609-2015-91-1-62-66.

Full text

Abstract:

Goal. To assess the effect of a combined cytostatic therapy and sulodexide on the functional condition of the vascular endothelium in psoriatic patients. Materials and methods. The authors examined 74 patients suffering from psoriasis vulgaris and exudative form of psoriasis. Depending on the treatment option, the patients were subdivided into two groups: Group I (n = 41) receiving a cytostatic therapy and Group II where patients received sulodexide as well. The severity of the endothelium dysfunction was assessed based on laboratory assessments such as nitrogen oxide and endothelin 1 in the b

APA, Harvard, Vancouver, ISO, and other styles

49

Li, Lin, Chenchen Li, Limin Zhang, Juan Ji, Yan Gao, and Wei Qin. "Efficacy of Yishen Tongluo Formula Combined with Sulodexide in the Treatment of Diabetic Nephropathy with Renal Failure." Urology Research 2, no. 4 (2025): 1–6. https://doi.org/10.26689/ur.v2i4.9318.

Full text

Abstract:

Objective: To analyze the effect of Yishen Tongluo Formula combined with sulodexide in treating patients with diabetic nephropathy and renal failure. Methods: A hundred patients with diabetic nephropathy accompanied by renal failure who were admitted to the hospital for treatment from March 2021 to March 2024 were randomly divided into the control group and the observation group, and were treated with sulodexide therapy and Yishen Tongluo Formula + sulodexide therapy, respectively. The treatment efficacy of the two groups was evaluated. Results: After treatment, fasting blood glucose and other

APA, Harvard, Vancouver, ISO, and other styles

50

Lunetta, M., and T. Salanitri. "Lowering of Plasma Viscosity by the Oral Administration of the Glycosaminoglycan Sulodexide in Patients with Peripheral Vascular Disease." Journal of International Medical Research 20, no. 1 (1992): 45–53. http://dx.doi.org/10.1177/030006059202000106.

Full text

Abstract:

The aim of the double-blind, crossover, placebo-controlled study was to evaluate whether oral administration of sulodexide, a medium molecular weight glycosaminoglycan, had an effect on whole blood, plasma and serum viscosity, and/or plasma fibrinogen concentrations. The drug was administered orally at a dose of 500 lipoproteinlipase releasing units twice daily for 1 month to two groups of 20 patients with peripheral vascular disease; one group was administered a placebo–drug sequence and the other a drug–placebo sequence. Orally administered sulodexide had a marked effect on plasma viscosity

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!